AR111752A1 - Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos - Google Patents

Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos

Info

Publication number
AR111752A1
AR111752A1 ARP180101158A ARP180101158A AR111752A1 AR 111752 A1 AR111752 A1 AR 111752A1 AR P180101158 A ARP180101158 A AR P180101158A AR P180101158 A ARP180101158 A AR P180101158A AR 111752 A1 AR111752 A1 AR 111752A1
Authority
AR
Argentina
Prior art keywords
btla
antibodies against
agonist antibodies
lymphocyte attenuator
antibodies
Prior art date
Application number
ARP180101158A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR111752A1 publication Critical patent/AR111752A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan anticuerpos que se fijan a BTLA, y métodos para usarlos, en donde dichos anticuerpos son útiles como agentes para tratar afecciones asociadas a la enfermedad autoinmunitaria, que incluyen el tratamiento de lupus.
ARP180101158A 2017-05-19 2018-05-03 Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos AR111752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
AR111752A1 true AR111752A1 (es) 2019-08-14

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101158A AR111752A1 (es) 2017-05-19 2018-05-03 Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos

Country Status (25)

Country Link
US (2) US10604573B2 (es)
EP (1) EP3625257A1 (es)
JP (2) JP6790304B2 (es)
KR (3) KR20220158847A (es)
CN (3) CN117402244A (es)
AR (1) AR111752A1 (es)
AU (2) AU2018269585B2 (es)
BR (1) BR112019021547A2 (es)
CA (2) CA3064518A1 (es)
CL (1) CL2019003215A1 (es)
CO (1) CO2019012756A2 (es)
CR (1) CR20190521A (es)
DO (1) DOP2019000293A (es)
EA (1) EA201992460A1 (es)
EC (1) ECSP19082184A (es)
JO (1) JOP20190261A1 (es)
MA (1) MA49133A (es)
MX (1) MX2019013604A (es)
MY (1) MY197425A (es)
NZ (1) NZ758360A (es)
PE (1) PE20191843A1 (es)
PH (1) PH12019502575A1 (es)
TW (4) TW202334237A (es)
WO (1) WO2018213113A1 (es)
ZA (1) ZA201906954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) * 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
MX2022004311A (es) 2019-10-15 2022-05-10 Lilly Co Eli Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
EP4232480A2 (en) * 2020-10-23 2023-08-30 AnaptysBio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2023143565A1 (en) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) * 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
CA2503125C (en) * 2002-10-25 2013-04-30 Hilary Clark Novel composition and methods for the treatment of immune related diseases
TW200837081A (en) * 2006-11-15 2008-09-16 Medarex Inc Human monoclonal antibodies to BTLA and methods of use
EA201270228A1 (ru) * 2009-07-31 2012-09-28 Медарекс, Инк. Полноценные человеческие антитела к btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
EP3383908A1 (en) * 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
KR20220158847A (ko) 2022-12-01
JP6790304B2 (ja) 2020-11-25
TW202334237A (zh) 2023-09-01
CR20190521A (es) 2020-01-06
TW201904991A (zh) 2019-02-01
TWI804044B (zh) 2023-06-01
CL2019003215A1 (es) 2020-04-13
JP2021019642A (ja) 2021-02-18
CO2019012756A2 (es) 2020-01-17
US10604573B2 (en) 2020-03-31
BR112019021547A2 (pt) 2020-05-12
ZA201906954B (en) 2021-06-30
CN110621699A (zh) 2019-12-27
CA3184628A1 (en) 2018-11-22
PE20191843A1 (es) 2019-12-31
KR102294051B1 (ko) 2021-08-27
DOP2019000293A (es) 2019-12-15
JP2020518288A (ja) 2020-06-25
US11396545B2 (en) 2022-07-26
US20200239578A1 (en) 2020-07-30
TW202233681A (zh) 2022-09-01
KR20210106033A (ko) 2021-08-27
TWI747043B (zh) 2021-11-21
CA3064518A1 (en) 2018-11-22
JOP20190261A1 (ar) 2019-11-05
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
EP3625257A1 (en) 2020-03-25
CN110621699B (zh) 2023-10-31
NZ758360A (en) 2022-10-28
TWI677504B (zh) 2019-11-21
CN117402245A (zh) 2024-01-16
AU2021277743A1 (en) 2021-12-23
WO2018213113A1 (en) 2018-11-22
AU2018269585A1 (en) 2019-10-31
US20180334502A1 (en) 2018-11-22
EA201992460A1 (ru) 2020-03-18
MA49133A (fr) 2020-03-25
ECSP19082184A (es) 2019-11-30
AU2018269585B2 (en) 2021-09-02
KR20190140969A (ko) 2019-12-20
PH12019502575A1 (en) 2020-07-13
MX2019013604A (es) 2019-12-18
CN117402244A (zh) 2024-01-16
MY197425A (en) 2023-06-16

Similar Documents

Publication Publication Date Title
AR111752A1 (es) Anticuerpos agonistas contra el atenuador de linfocitos b y t (btla) y sus usos
ECSP17070399A (es) Anticuerpos contra icos
CO2017006740A2 (es) Anticuerpos anti–cd79b
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
BR112017010481A2 (pt) agonista parcial de receptor de insulina, composição, dímeros de análogo de insulina e de insulina, método para tratar diabetes, usos de um agonista parcial de receptor de insulina e de um composto, e, composto.
CL2018000908A1 (es) Anticuerpos anti-lag3 y su uso para tratar cáncer o infección viral.
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
ECSP17063327A (es) Receptores de antígeno quiméricos anti–dll3 y métodos de uso
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
EA201890634A1 (ru) Агонисты глюкагонового рецептора
CO2019003047A2 (es) Anticuerpos anti-il-33 y usos de los mismos
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
CL2019002081A1 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas.
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
CL2020001753A1 (es) Composiciones y metodos para la liberación de ciclopropenos.
CL2019002802A1 (es) Anticuerpos biespecíficos anti-pd-l1-anti-tim-3.
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos